Introduction
Hepatocellular carcinoma (HCC) represents the sixth most common cancer and the third leading cause of cancer deaths worldwide (1) . Less than 30-40% of HCC patients are eligible for potentially curative therapies, including surgical resection and orthotopic liver transplantation due to advanced stages of disease at the time of diagnosis (2) . As a result, patients with advanced HCC receive systemic chemotherapy. The use of chemotherapy is often combined with transarterial chemoembolization (TACE), where the hepatic artery is obstructed (3) . However, chemotherapeutic treatment of HCC most frequently associates with the increased expression of drug resistance genes, resulting in the insensitivity to available chemotherapeutic agents (4) . Doxorubicin has shown inefficacy with a response rate of about 0-15% (5, 6) , and other chemotherapy agents, such as epirubicin, cisplatin, 5-fluorouracil, etoposide and their combinations, demonstrate even lower efficacies. For doxorubicin, one of the most important causes of chemoresistance is the increased expression of the ATP-binding cassette (ABC) transporters. Overexpression of the ABC member ABCB1 (MDR1) encoding P-glycoprotein (P-gp) is associated with lower accumulation of doxorubicin in HCC cells and with a worse prognosis (7) . Sorafenib represents the current treatment standard for advanced HCC by prolonging median survival of patients for about three month (8) . These limitations in treatment modalities strongly indicate the urgent need for novel alternative treatment options.
Cyclin-dependent kinases (CDKs) are fundamental for cell cycle control and regulation of apoptosis (9, 10) , and are found deregulated in most cancer cells. HCC shows frequent upregulation of CDKs through inactivation of CDK inhibitory proteins including p16
Ink4 , p21 WAF1/CIP1, p27 KIP1 and p57 KIP2 as well as through increasing levels of cyclins (11, 12) . In particular, CDK1 and CDK2 often show an aberrant regulation (13, 14) . CDK2 Thus, the targeting of CDKs has become an attractive approach in oncology (12) . A multitude of small molecule CDK inhibitors has been evaluated as promising antiproliferative agents for cancer therapy, including (R)-roscovitine (Seliciclib, CYC202).
Roscovitine is known to selectively inhibit CDK1, CDK2, CDK5, CDK7 and CDK9 activities through its binding to the ATP-binding site (20) . Currently, roscovitine is evaluated in a phase 1 clinical trial in combination with Sapacitabine with patients suffering from advanced solid tumors (NCT00999401) and in a phase 2 trial from non-small cell lung cancer patients (21).
The effects of roscovitine and its derivatives vary according to cell type, but they are generally able to block the cell cycle at every position (22). The cell cycle arrest is attributed to a direct inhibition of CDK1 and CDK2, while the induction of cell death by roscovitine is considered as a direct consequence of blocking the CDK7/CDK9-dependent transcription.
CDK7 is an integral component of the transcription factor TFIIH (23), which phosphorylates the Ser5 in the C-terminal domain (CTD) of RNA polymerase II (Pol II) to facilitate transcription initiation. CDK9, a portion of the elongation factor P-TEFb (24), performs a complementary function by phosphorylating Ser2 in the CTD of RNA Pol II, which is required for transcription elongation.
In this study we investigated the molecular mechanisms of two novel roscovitine derivatives, designated BA-12 and BP-14, in HCC cells and further determined their anticancer activity in xenograft models and chemically induced hepatoma. We show that both compounds inhibit CDK1 and CDK2 on their own, leading to the arrest of HCC cells in S/G2 and G2/M. Moreover, BA-12 and BP-14 reduce the phosphorylation of RNA Pol II at Ser5 
Material and Methods

Cell culture
The human hepatoma cell lines HepG2, PLC/PRF/5 (PLC), Hep3B and 3sp (formerly described as HCC-1.1) were cultivated as described (25, 26) . All cells were kept at 37°C and 5% CO 2 and were routinely screened for the absence of mycoplasma. The cell lines HepG2, PLC and Hep3B were obtained from the American Type Culture Collection. The 3sp cells were established from an HCC patient at the Medical University of Vienna (26) . All cell lines were verified by short tandem repeat analysis in November 2012.
Primary human hepatocytes (PHHs)
Non-neoplastic tissue samples from liver resections were obtained from patients undergoing partial hepatectomy for metastatic liver tumors of colorectal cancer. Experimental procedures were performed according to the guidelines of the charitable state controlled foundation HTCR (Human Tissue and Cell Research, Regensburg, Germany), with the informed patient's consent approved by the local ethical committee of the University of Regensburg. PHHs were isolated using a modified two-step EGTA/collagenase perfusion procedure as described previously (27) . Viability of isolated PHHs was determined by trypan blue exclusion and cells with a viability of more than 85% were used for further work. Cells were plated on collagen-coated plates (BD Biosciences, San Jose, USA) at a density of 1.2 x 10 5 cells/cm 2 . The medium consisted of DMEM with 10% FCS, 2 mM L-glutamine, 100 mg/ml streptomycin, 100 U/ml penicillin and supplements as follows: 125 mU/ml insulin, 7.3 ng/ml glucagon and 0.8 µg/ml hydrocortisone. Cells were incubated at 37°C in a humidified incubator with 5% CO 2 and media were changed daily. Figure S1A) and BP-14 (N2-(4-aminocyclohexyl)-9- Figure   S1B) were synthesized by procedures as described (28) . Compounds were dissolved in dimethylsulfoxide (DMSO). The stock solution of 100 mM was diluted in assay buffer or in medium to concentrations indicated in the text. The maximum concentration of DMSO in the assays never exceeded 0.1%.
Therapeutic agents
cyclopentyl-N6-[[6-(2-furyl)-3-pyridyl]methyl]purine-2,6-diamine) (Supplementary
Determination of cell viability and inhibitory concentration (IC) 50
Cell viability was determined using the 3-(4,5 dimethylthiazol-2-yl) - After incubation for 60 minutes at 30°C, the supernatant was boiled in sample buffer and separated by SDS-PAGE. Proteins were transferred to nitrocellulose membranes and stained with Ponceau S before analysis by autoradiography.
Clonogenic survival assay
500 cells were seeded in a 6-well plate and, either untreated or pretreated with BA-12 or BP-14 for 24 hours, incubated with standard medium for 10 days at 37°C and 5% CO 2 .
Colonies were fixed with methanol/acetic acid (3:1) and stained with 0.25% crystal violet.
The crystal violet of fixed cells was solubilized with 1% SDS and the absorbance was photometrically determined at 560 nm.
Cell proliferation analyzed by 5-Bromo-2'-deoxy-uridine incorporation
Cultured cells were grown in medium containing 10 µM 5-bromo-2'-deoxy-uridine 6 human hepatoma cells were resuspended in 100 μl Ringer solution and subcutaneously injected into severe combined immunodeficient (SCID) mice (Harlan Laboratories, San Pietro, Italy). Tumor volume was determined as described (29) .
Pharmacological intervention was performed in tumor-bearing mice for 17 days by daily intraperitoneal injection of either 5 mg/kg BA-12 or 1 mg/kg BP-14 in 100 µl of 0.01% DMSO. Control tumor-bearing mice received DMSO only. The experiments were performed using five mice per group and carried out according to the Austrian guidelines for animal care and protection.
Diethylnitrosamine-induced liver cancer and drug intervention
To initiate tumor development in the liver, 14-day-old male C57BL/6J mice were intraperitoneally injected with a single dose of diethylnitrosamine (DEN, 25 mg/kg). After 8 month, pharmacological intervention was administrated in DEN-induced mice by 3 cycles of treatment with compounds for 10 days and a release from compounds for 7 days between the cycles. 5 mg/kg BA-12 or 1 mg/kg BP-14 was intraperitoneally injected in 100 µl of 0.01% DMSO. Control mice received DMSO only. Thereafter, mice were sacrificed and livers were fixed in 4% formaldehyde. Two researchers (C.H. and M.G.) independently scored the diameters of neoplasia that could be monitored at the liver surface. Cancerous nodules with a diameter of up to 1 cm, covering more than 97% of all visible hepatomas, were included into the analysis. The experiments were performed using twenty mice per group and carried out according to the Austrian guidelines for animal care and protection.
Immunohistochemistry and TUNEL analysis
Mice were sacrificed and tumors were fixed as described (30 
Statistical analysis
Data were expressed as means ± standard deviation (SD) or standard error of the mean (SEM). The statistical significance of differences was evaluated using an unpaired, nonparametric Student's t-test. Significant differences between experimental groups were * p<0.05, ** p<0.01 or *** p<0.005. 
Results
Cytotoxicity and kinase specificity of BA-12 and BP-14
Novel derivatives of roscovitine, designated BA-12 and BP-14, were synthesized based on our knowledge of structure-activity relationships for roscovitine-related compounds (28, 31) . Cell viability assays showed strong cytotoxic effects of BA-12 and BP-14 on human HepG2 and PLC hepatoma cells (Fig. 1A and 1B) Table S1 ). Kinase assays using cell-free extracts showed that BA-12 or BP-14 significantly reduced CDK1/CDK2 activity at concentrations of 0.03 µM (Fig. 1C and   1D ). Notably, roscovitine showed no effect at this concentration which suggests less potency than BA-12 and BP-14 (Fig. 1C) . Furthermore, administration of HepG2 and PLC cells with 0.5 µM BA-12 or 0.2 µM BP-14, respectively, caused a significant decrease in CDK2-specific phosphorylation of retinoblastoma (Rb; Fig. 1E and 1F ). This was associated with a more moderate lowering of total Rb levels at higher drug concentrations that might be due to apoptosis. In the same line, treatment of HepG2 and PLC cells with 1 µM and 2 µM BA-12, respectively, resulted in a more than 2.5-fold reduction of RNA polymerase II phosphorylation on serine 5 (CDK7) and serine 2 (CDK9; Fig. 1E and 1F 
BA-12 and BP-14 abrogate clonogenicity and repress cell cycle progression
We observed a more than 15-fold reduction of clonogenic growth behavior after treatment of HepG2 and PLC cells with 1 µM BA-12 ( Fig. 2A) . BP-14-treated cells displayed loss of clonogenicity even at 0.2 µM (Fig. 2B) . Analysis of DNA synthesis revealed that treatment of HepG2 or PLC cells with 1 µM of either BA-12 or BP-14 decreased BrdU incorporation more than 2-fold as compared to control (Fig. 2C and 2D Fig. S3A and S3B ). Accordingly, both compounds induced an accumulation in the G2/M and S/G2 phase of the cell cycle ( Fig. 2E and 2F ). These data suggest that both BA-12 and BP-14 act anti-proliferative by blocking DNA replication and by arresting HCC cells in the S/G2/M phase of the cell cycle.
BA-12 and BP-14 induce apoptosis in hepatoma cells rather than in primary human hepatocytes (PHHs)
We next examined whether apoptosis is induced by BA-12 or BP-14 in HepG2 cells that harbor wild type p53 and in PLC cells expressing full length but mutated p53 (32) .
Administration of 1 µM BA-12 induced cleavage of PARP and p53 expression in HepG2 cells (Fig. 3A, left panel) . Comparable observations were made after treatment with 2 µM BA-12 in p53-mutated PLC cells (Fig. 3A, right panel) . BP-14 was able to trigger PARP cleavage even at a concentration of 0.2 µM (Fig. 3B) , thus being more potent to induce apoptosis as compared to BA-12. Cleavage of caspase-7 further confirmed data of PARP processing ( Fig.   3A and 3B ). As BP-14 induced apoptosis at 0.2 µM in the absence of CDK7/9 inhibition, these data suggest cytotoxic effects that are also independent of CDK7/9. Yet, both BA-12 hepatoma ( Fig. 3C and 3D) . Accordingly, both BA-12 and BP-14 exhibited IC 50 values of 26 µM and 20 µM in PHHs, respectively, which was 35-fold (BA-12) or 160-fold (BP-14) higher than observed in HepG2 cells (Supplementary Table S1 ). From these data we conclude that the novel CDK inhibitors induce apoptosis of HCC cells at low concentration in a p53-independent fashion and fail to execute cytotoxic effects in PHHs.
Long-term cytotoxicity of BA-12 and BP-14 in HCC cells
Most of the chemotherapeutic compounds that are currently available for HCC treatment show low cytotoxic efficacy presumably due to the modification and rapid removal from neoplastic hepatocytes by mechanisms of induced multiple drug resistance (33) . This poses one of the major problems in combating liver cancer. Therefore, we analyzed whether (Fig. 4A and 4B) . Interestingly, BP-14 exhibited a higher potency than BA-12 in the PLC model resulting in a more pronounced reduction of the tumor volume. Evaluation of S-phase-positive cells in HepG2-and PLC-derived tumors by BrdU incorporation into DNA revealed an up to 2-fold decrease after exposure to either BA-12 or BP-14 (Fig. 4C and   D) . Further analysis showed a 2-fold increase of TUNEL-positive cells after treatment of HepG2-derived tumors with BA-12 or BP-14, which was similar in PLC tumors, indicating that both compounds induce apoptosis in tumor tissues ( Fig. 4E and F) . Thus, cytostatic effects by reduced DNA synthesis and cytotoxic effects by augmented apoptosis explain the efficacy of these compounds.
We further analyzed the ability of BA-12 and BP-14 to interfere with endogenous liver cancer development that was chemically induced by the hepatotoxin DEN. Treatment modalities of DEN-induced mice included 3 cycles of treatment at MTDs of BA-12 and BP-14 for 10 days with interim breaks of 7 days (Fig. 5A) . Evaluation of tumor nodules that are observed on the surface of cancerous livers revealed that BA-12 causes a 1.4-fold decrease of tumor nodules size as compared to control mice. Intervention with BP-14 showed comparable anti-cancer effects by a 1.3-fold decline of DEN-induced hepatoma ( Fig. 5B and 5C ).
Noteworthy, mice treated with BA-12 and BP-14 did not show a decrease in body weight compared to control group (Fig. 5D) , suggesting that both compounds do not show obvious side effects. In summary, these data indicate that both BA-12 and BP-14 exhibit strong antihepatoma activities in vivo as observed in xenograft models as well as in endogenous liver cancer. 
Discussion
A considerable number of small molecule inhibitors of CDKs have been designed in order to block proliferation of cancer cells (34) . Inhibitors of the first generation include roscovitine, a 2,6,9-tri-substituted purine derived from studies evaluating the structure-activity relationship of this compound class (20, 35) . It is a selective inhibitor of CDK1/cyclin B, CDK2/cyclin E, CDK5/p35, CDK7/cyclin H and CDK9/cyclin T1. In this study we assessed the anti-cancer activities of the novel roscovitine derivatives BA-12 and BP-14 in hepatoma.
These compounds show a much higher potency than roscovitine as indicated by the inhibition of CDK1/2 in cell-free extracts (Fig. 1C) (31) 
overexpressing ABCB1. The P-gp overexpressing sublines demonstrated a lower sensitivity against BA-12 and BP-14 by showing IC 50 values, which were 2-fold higher than in parental cells (data not shown). Thus, these data propose BA-12 and BP-14 as substrates of P-gp. In agreement, several studies showed that roscovitine represents a high affinity substrate of P-gp as well, yet no concomitant ABCB1-mediated resistance could be observed after treatment with roscovitine (37) . Noteworthy, roscovitine was also shown to induce apoptosis in a doxorubicin-resistant human myeloma cell line that overexpresses P-gp (38) . Therefore we speculate that despite being P-gp substrates, BA-12 and BP-14 do not induce resistance and are thus being promising novel therapeutic agents with persistent anti-hepatoma activities.
BA-12 and BP-14 might be superior to currently available chemotherapeutics, but should be used as first line therapy due to the frequent upregulation of P-gp in drug-treated HCC patients.
Roscovitine is effective in antagonizing CDKs prior to its processing by either glucuronidation or cytochromes P450-mediated metabolism. The cytochromes P450 CYP3A4 and CYP2B6 generate the carboxylate PMF30-128 as major metabolite that lacks inhibitory function on CDKs (39) . Glucuronidation takes place via the UDP-glucuronosyl-transferases (UGTs) 1A1, 1A3 and 2B7 (39, 40) . Although not tested yet, we assume that BA-12 and BP-14 are metabolized in a similar way. Currently running experiments focus on the uptake and metabolism of these drugs and investigate whether the compound clearance via 1A1, 1A3 and 2B7 is much more reduced as compared to roscovitine. We further hypothesize that glucoronidation might be the cause for the higher potency of BP-14 as compared to BA-12.
BA-12 harbors a hydroxyl group that gets oxidized to glucuronic acid and is thus much more water soluble leading to a more rapid elimination from the body. Both compounds are able to reduce cell invasion and migration of 3-dimensional hepatospheres into the surrounding extracellular matrix (data not shown). In accordance with these findings, CDK7 was found to affect the migration of ovarian, breast, melanoma and prostate cancer cell lines (44) . In the same line, CDK9 was shown to be involved in cancer cell invasion, as miR-34a suppresses the assembly of the CDK9-c-Myc-P-TEFb complexes, leading to an inhibition of cell migration and invasion (45) . CDK9 further induces tumor necrosis factor-alpha mediated expression of matrix metalloproteinase-9 that facilitates tumor dissemination (46) . In addition, inhibition of CDK5 is suggested to be beneficial for anticancer therapy as CDK 5 stimulates Rac1-dependent migration of endothelial cells during tumor angiogenesis (47) . The putative multiple inhibitory roles of BA-12 and BP-14 in hepatoma growth and migration make them promising new drugs that must be considered for clinical investigation. 
